Annovis Bio (ANVS) closed at $0.74 on November 17, 2026, down 0.9% from the previous close, on volume of 1,850,999 shares (30-day average 2,477,616).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Azora Therapeutics (AZR)
TipRanks (Tue, 17-Nov 11:20 AM ET)
Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study
Globe Newswire (Tue, 17-Nov 8:00 AM ET)
Canaccord Genuity Reaffirms Their Buy Rating on Annovis Bio (ANVS)
TipRanks (Mon, 16-Nov 7:16 AM ET)
Annovis Bio GAAP EPS of -$0.22 beats by $0.08
Seeking Alpha News (Fri, 13-Nov 8:07 AM ET)
Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
Globe Newswire (Fri, 13-Nov 8:00 AM ET)
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
Globe Newswire (Thu, 12-Nov 8:00 AM ET)
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Annovis Announces Pricing of $21.0 Million Public Offering
Globe Newswire (Thu, 5-Nov 8:05 AM ET)
Annovis Announces Launch of Proposed Public Offering
Globe Newswire (Wed, 4-Nov 4:07 PM ET)
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
Globe Newswire (Fri, 30-Oct 5:00 PM ET)
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Annovis Bio trades on the NYSE stock market under the symbol ANVS.
As of November 17, 2026, ANVS stock price declined to $0.74 with 1,850,999 million shares trading.
ANVS has a beta of 2.33, meaning it tends to be more sensitive to market movements. ANVS has a correlation of 0.08 to the broad based SPY ETF.
ANVS has a market cap of $31.97 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ANVS traded as high as $22.49 and as low as $.62.
The top ETF exchange traded funds that ANVS belongs to (by Net Assets): VTI, VXF, IWC, BUSM.
ANVS has underperformed the market in the last year with a price return of -68.2% while the SPY ETF gained +10.1%. ANVS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -59.8% and -31.2%, respectively, while the SPY returned -5.4% and -2.6%, respectively.
ANVS support price is $.69 and resistance is $.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANVS shares will trade within this expected range on the day.